Aidixi plus BCG showed strong early efficacy and manageable safety in patients with high-risk, HER2-expressing ...

OSLO, Norway, April 29, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light ...

The Phase 3 BOND-003 Cohort C study is in patients with high-risk non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG) treatment with carcinoma in situ (CIS ...

CG Oncology shares rose Monday after the company shared positive data from a study of its bladder-cancer treatment. The stock gained 39% to $31.10 in premarket trading. The Irvine, Calif., ...

UGN-102 achieved a median 24.2-month duration of response in recurrent low-grade intermediate-risk bladder cancer patients. Today's manic market swings are creating the perfect setup for Matt’s ...

The Phase 3 BOND-003 Cohort C study is in patients with high-risk non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG) treatment with carcinoma in situ (CIS) with ...

Over the last years, many biological markers emerged that act as an adjunct for the detection of early bladder cancer recurrence. Some of these markers had a proven better sensitivity and ...

Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer trial. But the study fell short of a clean sweep of positive outcomes ...

The subtypes investigated in bladder cancer were CK19, CK20 and CK7 IHC/RT-PCR CK20: 56–46% [98,99]; CK7: 100% [99]; CK1: 93.1% [101] Association of CK19 with UPII detected pN0 patients with ...

A phase 3 trial of Johnson & Johnson's TAR-200 therapy in bladder cancer has failed to show efficacy, although the company is still confident in the potential of the programme. The SunRISe-2 study ...